Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Abcellera Biologics Inc expected to post a loss of 1 cent a share - Earnings Preview

* Abcellera Biologics Inc  ABCL.OQ   ABCL.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
21. 
    * The Vancouver British Columbia-based  company is expected
to
report  a 63.5% decrease in revenue to $50.801 million from
$139.33 million a year ago, according to the mean estimate from
9 analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Abcellera Biologics
Inc
is for a loss of 1 cent per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Abcellera
Biologics Inc is $29.5​, above​ its last closing price of $9.50.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  0.05        0.05       0.08      Beat    76.1
 Jun. 30 2022  -0.01       -0.02      -0.02     Met     -28.5
 Mar. 31 2022  0.40        0.38       0.54      Beat    40.6​
 Dec. 31 2021  0.18        0.19       0.19      Met     0.6
 ​​Sep.        -0.07       -0.05      -0.08     Missed  -52.4
 30 2021                                                
 Jun. 30 2021  0.07        0.08       -0.01     Missed  -112.9
                                                        ​
 Mar. 31 2021  0.36        0.38       0.37      Missed  -2.2
 Dec. 31 2020  0.63        0.61       0.44      Missed  -27.9
 This summary was machine generated February 17 at 21:47 GMT. 
All figures in US dollars  unless otherwise stated

Recent news on AbCellera Biologics

See all news